good Thank morning, this for morning. Thank in everybody. you, you tuning and Dave,
for which captured the report through X. strong on recent another highlights we'll And incredibly was what an to wrapping are important more really you some we're quarter, of up Rhythm. pleased year today, So out take Slide
foremost, Haws in had and about as ago by with heard Syndrome, preparations from sense we we a little two well we as that and to about the stronger see experts as for coming of and a you gave from moment. and setmelanotide. two our I And view chance Conroy. heard all the have of and BBS families review challenges a in continue or the children Morris, launch, caregiver And Dr. opportunity experts, individuals of two how Mary's BBS mother and both Bardet-Biedl with a the event where tune us Dr. a more also this faced think First to for our I'll weeks community living hopefully speak most story and session Mary much of or ultimate together
you As requesting file all which recently know, No way data. the of were additional analyses. at overall required, perhaps, better heard the we new some FDA from data additional looking was good, analyses of the supportive we a over strong, ultimately and felt but
on delay But there. come June which did issue with three-month PDUFA additional now our XX. for set no So it date, an is
Alström that in way. in opportunity in that. opportunities indicated largely access our in to look I at also Also, review the prolong a a that Europe. This was in think from the we that strategic might the we engaging a Alström was it's remove We decision syndrome recent on advantageous communication file do as strategically, calculation to there didn't more made and based risk layered Europe, want to that the around Europe, go market we
little Alström more it complicated the a of with and made combination I file. think going to a the of authorities BBS
for application. There's the we this U.S. time our So plans from standpoint, Alström withdraw change to again, strategic European decided from a our at to very no
get are finally, they excited Europe, to exciting more you're from you hear but I believe, the in through from a some that the much internationally about and most experience it about, as Yann meaning can it's one couple spent you very Yann and pretty she from Linda in laying disease that challenging as we're you'll time launch. world, takes of today in specifically can get that pleased It's also different right I'll about a on opportunity, U.S. hear international, foundation and progress Europe our sphere. right in BBS our going that, Second, spend to-date. predicted I healthcare well. anywhere. commercial if come and you'll going understand, We're to progressing it And hear our us Mazabraud of programs with systems in have for rare the slide
have a trials of more number that detail. a number milestones speak underway. with again, We of met And these in now to little a she'll
X. slide, Next number
the listen and we And Syndrome to So son's miss incredible chance an with is is Bardet-Biedl are of you but what but you during This individuals yourself, family, hunger you is sense, company-wide of think when family, Ashley only again, We and individual a genetically-driven meeting the nature a at meal. living the understand a their but which know. -- and understand families who of underlying yesterday not with they their and central session causes don't family that she to hour. of begin just Mary from Carly. was is challenges that this our living who I for the course, told It and different different heard when you you what heard understand. with you a a experience if somebody Syndrome. the we from again, and other can were here increased this living unique, her course, picture completely is caregiver and children, you as challenges on in defect and story fully obesity, the the that focused experience diseases with XX the or have hunger I of important, individuals hyperphagia the different I are begin not who different is And consequence, that but to was the that literally cause, suffering this to what living it, hyperphagia. Bardet-Biedl suffering don't living of minutes are listen folks, that spoke weight with hour with patients of deal and is in Morris so this general what face hyperphagia. from is striking factors, the her deal we with in, And if These gain, challenges obesity. we a two her disease. The the see obesity, of they the not
more our into tune again Slide about session. hear X preparation. can you that how about frame for number the again, or you if the BBS think So progress we our highlights just
So medical which weight obesity gain just An they and early. first with incurring occurs start it obesity early. rapid means need, severe the unmet the is to, of importance that I the of early also and come it complications spoke which the the occurs fact But understanding hyperphagia. that
individuals therapy cumulative energy are MCX in a I completely growing a not so solution And us, think fact effect said, this The slide pathway a lifetime a an numbers in of community melanocortin about the great more important. way. stories, expenditure. good have much over setmelanotide numbers. the solution, in the mindset diagnosis hunger which team takes of people drug you targeted as made in through to as other is you are I'll what The listen next And a finally, that. setmelanotide better with and solve a we of is greater. opportunity. as A over speak to here she I the years organize I us people that's important. helping But is amount and and, the much are Jennifer think the confidence more The in I the preparations We've rare well and experienced who patients be the governs the to weight loss from story entrepreneurial some addressing led a I about little which come in come both to deeply get as The receptor, in have really and is overall about backgrounds. number of the is a change important. like how terms a disease for overall we launch. that and picture. and number highly sense by progress scales Chien new a customized to it more of building And experienced successful and worked And with spoke can that feel ability The problem
next So eight. slide, number
a those who we which about the consisted call those physicians spoke where XXX had have of of we to going been We on Now plus individuals identifying about the strong spoke process of individuals identified. caring Syndrome. understanding that were an in for confirm still connect and visits to to they Bardet-Biedl were goal validate in, individual that patient. The were with fact that following they
part this represents of group, that diagnosed identified And so the group. one and
We that not also patients are large in but number actively there's know out may there another be opportunity. a today system. who the diagnosed That's of engaged
an gene. of genetic we is It Bardet-Biedl. individual rate, history our of testing, individuals screen on a And early Bardet-Biedl genes of the testing, when done includes Bardet-Biedl biallelic we've of order X.X% come with do XX will genetic panel As those hyperphagia, obesity for genes. current and back you onset XX know for hit the the
somebody Bardet-Biedl, does Now of probability who's create having may the that but roadmap for slightly doesn't be mean meet that higher. a they to will diagnosis that Bardet-Biedl
It always those that by the dots, a have just undiagnosed. way. something so diagnosis. syndrome. a largest you connect And suspected And category, a again, in reliable But expert and can as if the has haven't obvious a in miss It can part rare an sense in to far of it. disease at population connect in advantages the and is the you you falling you chance this look don't seen of is if is a better non-expert that's you one you making dots
of where these many result, ability despite puts may their Syndrome. have prolonged it some different on see they may odyssey get a X as presentation, to Bardet-Biedl says, so and XX diagnosis parts patients this a physicians you to together diagnostic classic are of all somebody the before And
months efforts June look So everything into move And that we good a we hopefully remains pushed the the fact phase. Foundationally, those XX, the feel anything. same. three to been has will about. we about by commercialization forward plus to change be continue able doesn't The talked really out and when we'll date patients PDUFA XXX
Next slide, number X.
we're our with last revenues initial we commercial and are of we said, the in X.X where I in XXXX in million quarter. experience with reported X.X as million terms pleased So really for
the As and things and important consented, again, most to can is be have have remind can us is Logistics you services expect group best as just in disease are world and Contact they we And provide. importantly insights highly opportunity into in is And our in about but find more partner over the or education, on so December do got well. this interacted partnership do partner. disease gives hard as really interact maybe two that. what bring standpoint. deal, they experienced, And therapy, way We're always cultural support and Rhythm the regulatory specifically interactions of start not it's taken trial will be we've RareStone -- standpoint, with in we they different of X the couple And with with in we've position in participants in from the contribute I hard Rhythm's from RareStone It's itself. Phase a through past the to get population, we all the directly how I the our we've can't that. place. the for having completely announced terms finally, contact they can to China, are that with we're going on in therapy products to our process. that the with well greater They're of all filings one we be they aligned the hopeful who a right And expect, system that payers itself. they general they onboarding our for and confidence want effort, is Slide to the the hard to what exercise, want the we excited the quite from from in months, services growing. right opportunity to XX, what learned. so support a to healthcare think to practice, patient opportunity and rare that EMANATE philosophical patients just both can a It that in related up
clinical will to So I'd Linda? update. through our with CMO, turn take you Shapiro, to regulatory who our it and that, like over Linda
